Inclusion Criteria

- INCLUSION CRITERIA:

- Patients with known lymphoid malignancy or precursor disease to a lymphoid
malignancy, including multiple myeloma, B-cell and T-cell lymphomas: including but
not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin's lymphoma (HL),
multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell
leukemia/lymphoma (ATL).

- Confirmed pathological diagnosis.

- At NCI site, the diagnosis is required from the Laboratory of Pathology, NCI.
Tumor tissue that has been previously collected and is available for study or
that can be collected with minimal additional risk to the subject during
sampling required for routine patient care or required testing on an NIH
research protocol will be used for diagnosis.

- At the UWI site, diagnosis is as required per contract HH5N261200800011C.

- Greater than or equal to 18 years of age.

- ECOG performance 0-2.

- Must be willing and able to provide informed consent.

INCLUSION FOR APHERESIS:

- Hemoglobin greater than or equal to 10 milligrams per deciliter and platelet count
greater than 75,000 per cubic millimeter.

- Weight greater than 25 kilograms

- HIV negative

- Prothrombin Time - within normal limits

- Partial Thromboplastin Time - within normal limits

- Medically indicated central line in place or adequate peripheral venous access

EXCLUSION CRITERIA:

- Pregnant or breast feeding women will not be eligible for any aspect of this protocol
except phlebotomy.

- Active symptomatic major organ disorder that would increase the risk of biopsy or
apheresis, including but not limited to ischemic heart disease, recent myocardial
infarction, active congestive heart failure, pulmonary dysfunction.

- Active concomitant medical or psychological illnesses that may increase the risk to
the subject or inability to obtain informed consent, at the discretion of the
principal investigator.